Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MOR209/ES414 |
Synonyms | |
Therapy Description |
MOR209/ES414 is a humanized bispecific antibody that binds to prostate specific membrane antigen (PSMA) and CD3 complex simultaneously, therefore crosslinking PSMA-expressing tumor cells and cytotoxic T-lymphocytes, resulting in tumor cell death (PMID: 27406985). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MOR209/ES414 | PSMA Antibody 20 | MOR209/ES414 is a humanized bispecific antibody that binds to prostate specific membrane antigen (PSMA) and CD3 complex simultaneously, therefore crosslinking PSMA-expressing tumor cells and cytotoxic T-lymphocytes, resulting in tumor cell death (PMID: 27406985). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02262910 | Phase I | MOR209/ES414 | Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer | Completed | USA | AUS | 0 |